http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AbbVie to Host Second-Quarter 2020 Earnings Conference Call
-
UPDATE: AbbVie (ABBV) Company, Allergan, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
-
Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
-
AbbVie (ABBV) Reports FDA to Review sNDA for IMBRUVICA (ibrutinib); Seeks to Expand U.S. Label with Long-Term Data in Waldenstrom's Macroglobulinemia
-
IMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström's Macroglobulinemia (WM)
-
AbbVie (ABBV) Announces RINVOQ Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
-
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
-
RINVOQ™ (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
-
Alpine Immune Sciences (ALPN), AbbVie (ABBV) Announce Option and License Agreement for Development and Commercialization of ALPN-101
-
Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101
-
AbbVie Declares Quarterly Dividend
-
AbbVie (ABBV) Announces FDA Approves JUVEDERM VOLUMA XC for Enhancement of Chin Region
-
FDA Approves JUVÉDERM® VOLUMA™ XC for Enhancement of the Chin Region
-
AbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society
-
VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients
-
AbbVie Recommends Shareholders Reject TRC Capital's "Mini-Tender" Offer
-
AbbVie (ABBV) Presents New Late-Breaking Data Showing SKYRIZI Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX at 52 Weeks
-
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
-
AbbVie (ABBV) Reports Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with RA
-
Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis
-
Genmab (GMAB) and AbbVie (ABBV) Announce Broad Oncology Collaboration, Genmab to Receive Upfront Payment of $750M With Total Potential Milestones of Up to $3.15B
-
Genmab and AbbVie Announce Broad Oncology Collaboration
-
AbbVie and Genmab Announce Broad Oncology Collaboration
-
AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
-
AbbVie (ABBV) Enters Collaboration with Harbour BioMed, Utrecht University and Erasmus Medical Center to Develop Monoclonal Antibody Therapy to Prevent & Treat COVID-19
-
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
-
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
-
AbbVie (ABBV) Announces New Long-term Data from RINVOQ Phase 3 Studies in Rheumatoid Arthritis Presented at EULAR
-
New Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
-
AbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference
-
AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for RINVOQ for Treatment of Adults with Active Psoriatic Arthritis
-
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
-
Allergan Aesthetics Launches Dedicated Multi-Channel Campaign To Contact Patients Who May Not Be Aware Of The BIOCELL® Recall And To Improve Tracking Information For U.S. Breast Implant Patients
-
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
-
AbbVie (ABBV), Neurocrine (NBIX) Announce FDA Approves First Oral Medication for Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
-
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
-
AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
-
Ironwood Pharma (IRWD), AbbVie (ABBV) Report Top-Line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with IBS-D
-
AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio
-
AbbVie to Present at the UBS Virtual Healthcare Conference
-
AbbVie (ABBV) Completes Acquisition of Allergan (AGN)
-
AbbVie Completes Transformative Acquisition of Allergan
-
AbbVie (ABBV), Allergan (AGN) Merger Cleared by FTC
-
AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan
-
AbbVie Reports First-Quarter 2020 Financial Results
-
AbbVie (ABBV) Announces IMBRUVICA Received 11th FDA Approval
-
IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
-
AbbVie to Host First-Quarter 2020 Earnings Conference Call
-
AbbVie Donates $35 Million for COVID-19 Relief to Support Healthcare Systems, Patients and Communities
-
AbbVie (ABBV) Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA in Combination with Azacitidine in Patients with AML

